Episode 18: Preventing Tonic-Clonic Seizures in Refractory Epilepsy

September 25, 2020
Matt Hoffman
Matt Hoffman

Matt Hoffman, Senior Editor for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He hosts the NeurologyLive Mind Moments podcast, as well as Second Opinion on Medical World News. Follow him on Twitter @byMattHoffman or email him at mhoffman@neurologylive.com

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with David Vossler, MD.

Episode 18 of the NeurologyLive Mind Moments podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 18, "Preventing Tonic-Clonic Seizures in Refractory Epilepsy," features an interview with David Vossler, MD, professor, and medical director, The Neuroscience Institute, UW Medicine Valley Medical Center. He discussed the findings of a recently published phase 3 dataset on lacosamide, also known as Vimpat, and its effects on reducing genetic generalized onset tonic-clonic seizures (previously known as primary generalized tonic clonic seizures).

Click here to subscribe to the Mind Moments podcast. Thanks for listening!